Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 18 and 75 years old at the time of signing the consent form
- People whose doctors estimate they are likely to survive for more than 12 weeks
- People who are generally able to carry out everyday activities with little or no physical limitation (confirmed by a standard doctor's assessment called an ECOG score of 0 or 1)
- People who have a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back after treatment or has not responded to treatment
- People whose liver, kidneys, heart, and other organs are working at an adequate level
Who may not be able to join:
- People whose AML is a specific subtype called Acute Promyelocytic Leukemia (APL)
- People whose leukemia is a specific subtype called Mixed Phenotype Acute Leukemia (MPAL)
- People whose leukemia is a specific subtype called Acute Undifferentiated Leukemia (AUL)
- People whose leukemia is only present outside the bone marrow, with no involvement in the bone marrow itself
- People with a known allergy to any ingredient in the trial treatment called A-CAR028
- People with serious heart conditions, including a heart attack, artery procedure, or stent placement within the past 12 months, unstable chest pain, serious irregular heartbeat, a history of severe heart muscle disease, or heart failure
- People who have had a stem cell transplant (either from their own cells or from a donor) within the 3 months before signing the consent form
- People whose leukemia has spread to the brain or spinal cord, or who have symptoms suggesting this may be the case
- People who have had a stroke or seizure within the 12 months before signing the consent form
- People who have had another type of cancer within the past 5 years
- People with an active infection that is not currently under control
- People who test positive for Hepatitis B, Hepatitis C, HIV, syphilis, or an active CMV infection
- People who have received a live vaccine within the 4 weeks before signing the consent form
- People who have active graft-versus-host disease (a complication that can occur after a donor transplant) at the time of screening
- People who have not waited long enough after their previous treatment before entering the trial (confirm with trial site)
- People who have previously been treated with CAR-T cell therapy or any other genetically modified T cell therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0571-87236898
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose limiting toxicities (DLTs); Incidence and severity of Treatment Emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.